Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Main Article Content

Michael Migden
Alexander Guminski
Ralf Gutzmer
Carmen Loquai
Nicholas Squittieri
Peter Foley


sonidegib, basal cell carcinoma, Hematology assessments, Hedgehog pathway inhibitor, Oncology, Advanced basal cell carcinoma


1. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

2. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

3. Odomzo (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002839/WC500192970.pdf.

5. Swissmedic, Authorization Number 65065, 2015. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/odomzo--200mg--kapseln--sonidegibum-.html.

6. Australian Government Department of Health, ARTG 292262. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02511-1&d=2018030216114622483.

7. Dummer R, et al. Br J Dermatol. 2020;182(6):1369–78.

8. Dummer R, et al. J Am Acad Dermatol. 2016;75(1):113–25.e115.

9. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

10. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

11. Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

Most read articles by the same author(s)

1 2 3 > >>